BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
See the famous winged horse Pegasus fly in the autumn night sky - 2A definitive Manual for Web based Mastering and Expertise Improvement
- 3Step by step instructions to Keep up with the Life span of Your Kona SUV's Battery Duration
- 4Extraordinary Miracles: The Cherished Islands for a Tropical Get-away
- 5The Best Games Crossroads in History
- AI is making spacecraft propulsion more efficient – and could even lead to nuclear-powered rockets
- Mating injuries may lead scientists to identify dinosaurs’ sex
- Getting through a Lifelong Change: Individual Examples of overcoming adversity
- Vote In favor of Your Favored Pet Consideration Administration
- Figure out How to Put resources into Lab Precious stones
- Brazil's agricultural research agency gets cannabis research greenlight
- 6 Popular Ladies' Aromas On the planet
- Vote in favor of Your #1 Home Exercise Gear: Execution and Comfort Matter
- Monetary Strengthening: Assuming Command over Your Cash
